Lunate Capital Ltd — 13F Holdings & Portfolio

CIK 2056786 · latest 13F-HR filed 2026-04-16

Lunate Capital Ltd manages $120.4M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are RVMD (44.36%), SAIL (33.00%), LINE (16.33%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 2, and trimmed 4.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$120.4M

Long-equity book

Holdings

6

Distinct positions

Period

2026-03-31

Filed 2026-04-16

Q/Q Activity

+0 / −0 / ↑2 / ↓4

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • REVOLUTION MEDICINES INC$382.5K +90.4%
  • NEUMORA THERAPEUTICS INC.$339.9K +8.9%
Show all 2

Top Trims

  • REVOLUTION MEDICINES INC-$121.5M -69.5%
  • SAILPOINT INC-$21.0M -34.6%
  • LINEAGE INC-$1.3M -6.4%
  • NAVAN INC-$768.0K -22.5%
Show all 4

New Positions

  • No new positions this quarter.
Show all 0

Exited Positions

  • No exits this quarter.
Show all 0
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 REVOLUTION MEDICINES INC RVMD 76155X100 $53.4M 44.36% 549,050 SH
2 SAILPOINT INC SAIL 78781J109 $39.7M 33.00% 3,000,000 SH
3 LINEAGE INC LINE 53566V106 $19.7M 16.33% 600,000 SH
4 NEUMORA THERAPEUTICS INC. NMRA 640979100 $4.1M 3.44% 2,124,143 SH
5 NAVAN INC NAVN 639193101 $2.6M 2.20% 200,000 SH
6 REVOLUTION MEDICINES INC RVMDW 76155X118 $805.5K 0.67% 450,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-04-16 $120.4M 6 0001011438-26-000235
2025-12-31 2026-01-23 $264.3M 6 0001011438-26-000036